ALPCO Announces the European Commercial Launch of FDA 510(k) Cleared Calprotectin Immunoturbidimetric Assay and Patient Enrollment in Pivotal US Clinical Trial for Automated Chemiluminescent Version

ALPCO Announces the European Commercial Launch of FDA 510(k) Cleared Calprotectin Immunoturbidimetric Assay and Patient Enrollment in Pivotal US Clinical Trial for Automated Chemiluminescent Version

SALEM, N.H., May 8, 2025 /PRNewswire/ -- American Laboratory Products Company, Ltd. ("ALPCO"), a global provider of specialty diagnostic solutions, announced the European commercial launch of its Calprotectin Immunoturbidimetric Assay, expanding its portfolio of gastrointestinal (GI) diagnostic solutions globally.